At a time when many large pharma companies are slashing costs and cutting deals, blood plasma therapeutics specialist CSL Limited is increasing R&D spending to build value, says the company's CEO Paul Perreault. Perreault says the company's R&D model has led to FDA approval on first submission for 85% of the company’s product filings. He adds that the company's Kcentra drug, which was recently approved for warfarin reversal, provides the first major change in transfusion medicine in the last fifty years. Finally, Perreault says the $31.5B company has the balance sheet to make acquisitions but will not rush into unnecessary, expensive deals simply to add to the top line.
Stocks in this video: